All In Biotech

Drug Trial Radar · NCT03284502

HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase Ib, Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

148

Actual

Start

May 22, 2017

Primary completion

Sep 30, 2024

Study completion Dec 31, 2024

Sponsor

Sponsor type
Industry
First posted
Sep 15, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the safety, tolerability and pharmacokinetics of HM95573 In combination with either cobimetinib or cetuximab in patients with locally advanced or metastatic solid tumors.

Conditions

  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor

Interventions

  • HM95573, cobimetinibDrug

    Regimen: twice daily (BID), continuous dosing for HM95573, once daily (QD) 21 days, 7 days off for cobimetinib

  • HM95573, cetuximabDrug

    Regimen: twice daily (BID), continuous dosing for HM95573

  • HM95573, cobimetinibDrug

    Regimen: Recommended dose (RD) and schedule selected based on the data of safety, tolerability, pharmacokinetics, and anti-tumor activity tested in Stage 1

  • HM95573, cetuximabDrug

    Regimen: Expansion dose of HM95573 selected based on the data of safety and tolerability tested in Stage 1b

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest as assessed by CTCAE v4.03Time frame: up to approximately 3 years
  2. Number of patients with DLTsTime frame: 28 days
  3. MTDs of HM95573 and cobimetinib, or HM95573 and cetuximabTime frame: End of Stage 1, an approximately 2 years
  4. Recommended Phase II dose (RPIID) of HM95573 and cobimetinib, or HM95573 and cetuximabTime frame: End of Stage 1, an approximately 2 years

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Dong-A University Hospital

    Pusan, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Yonsei University Health System Severance Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Borame Hospital

    Seoul, South Korea

  • National Cancer Center

    Goyang-si, Gyeonggi-do, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • Chonnam National University Hwasun Hospital

    Hwasun, Jeollanam-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.